Teleflex/Genzyme Biosurgery
This article was originally published in The Gray Sheet
Executive Summary
Plymouth Meeting, Penn. firm gains minimally invasive heart surgery and vein harvesting systems, aortic punch product lines, and cardiovascular and valve suture devices, through purchase of Genzyme Biosurgery's cardiothoracic devices business. Teleflex will pay Genzyme $32.4 mil. in cash and $8 mil. in assumed trade obligations. The cardiothoracic product lines earned $76 mil. in revenues in 2002...
You may also be interested in...
Teleflex Medical Enhances U.S. Disposable Offerings With Hudson Buy
Teleflex Medical's Rusch brand of healthcare supplies will gain increased access to the U.S. market through the $460 mil. acquisition of Hudson Respiratory Care
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.